Textbook of Hemophilia

Professor Christine A. Lee, Consultant in Haematology, Royal Free Hospital, London Dr Keith Hoots, Gulf State Hemophilia Center, University of Texas Health Sciences Center, USA Dr Eric Berntop, Malmo University Hospital, Sweden

Contributors.Foreword.Part I: Introduction.1 Overview of Hemostasis.2 Cellular Processing of Factor VIII and IX.3 Work-up of a Bleeding Adult.Part II: HEMOPHILIA A.4 Molecular Basis of Hemophilia A.5 Hemophilia A: Role of Factor VIII in Coagulation.6 Natural History of Inhibitor Development in Children with Severe Hemophilia A Treated with Factor VIII Products.7 Prophylaxis.8 Continuous Infusion of Coagulation Products in Hemophilia.Part III: Inhibitors to Factor VIII.9 Inhibitors to Factor VIII - Immunology.10 Inhibitors to Factor VIII - Molecular Basis.11 Inhibitors to Factor VIII - Epidemiology and Treatment.12 Inhibitors to Factor VIII - Mid and Moderate Hemophilia.13 Inhibitors to Factor VIII/IX: Treatment of Inhibitors - Immune Tolerance Induction.14 Inhibitors of Factor VIII: Treatment of Acute Bleeds.Part IV: Acquired Hemophilia.15 Acquired Inhibitors to Factor VIII.Part V: Hemophilia B.16 Hemophilia B - Molecular Basis.17 Inhibitors in Hemophilia B.18 Treatment Inhibitors in Hemophilia B.Part VI: Pharmacokinetics of Factors VIII & IX.19 Pharmacokinetics.Part VII: Pediatrics.20 Work-up of a Bleeding Child.21 Care of the Child with Hemophilia.22 To Neonate with Hemophilia.Part VIII: Products Used to Treat Hemophilia.23 Products Used to Treat Hemophilia: Evolution of Treatment for Hemophilia A and B.24 Products Used to Treat Hemophilia: Recombinant Products.25 Products Used to Treat Hemophilia: Plasma-Derived Coagulation Factor Concentrates.26 Products Used to Treat Hemophilia: Recombinant Factor VIIa.27 Products Used to Treat Hemophilia: Dosing.28 Products Used to Treat Hemophilia: Regulation.Part IX: Muscoskeletal.29 Joint Replacement.30 Synovioarthesis in Hemophilia.31 Pseudotumours in patients with Hemophilia.32 Radiology.33 Magnetic Resonance Imaging/ Joint Outcome.34 Physiotherapy in the Management of Hemophilia.Part X: Transfusion-Transmitted Disease.35 Transfusion Transmitted Disease: History of Epidemics (Focus on HIV).36 Transfusion Transmitted Disease: Hepatitis C Virus Infection and Liver Transplantation.Part XI: Gene Therapy.37 Gene Therapy: Introduction and Overview.38 Gene Therapy for Hemophilia B.39 Gene Therapy for Hemophilia A.40 Gene Therapy: Molecular Engineering of Factor VIII and Factor IX.Part XII: Laboratory.41 Laboratory Assays in Hemophilia.42 Standardization of Assays.Part XIII: Obstetrics & Gynaecology.43 Obstetrics and Gynecology: Hemophilia.Part XIV: Von Willebrand Disease.44 von Willebrand Disease: Molecular Aspects.45 von Willebrand Disease: Epidemiology.46 von Willebrand Disease: Biological Diagnosis.47Classification and Clinical Aspects of von Willebrand Disease.Part XV: Treatment of Von Willebrand Disease.48 Treatment of von Willebrand Disease: Desmopressin.49 Treatment of von Willebrand Disease: Therapeutic Concentrates.50 Women & Von Willebrand Disease.Part XVI: Rare Bleeding Disorders.51 Factor II.52 Factor V and combined Factor V and VIII Deficiencies.53 Congenital Factor VII Deficiency.54 Factor X and Factor X Deficiency.55 Factor XI Deficiency.56 Factor XIII.57 Fibrinogen.58 Miscellaneous Rare Bleeding Disorders.XVII: Quality of Life.59 Quality of Life in Hemophilia.XVIII: Economics.60 The Economics of Hemophilia Treatments.XIX: Comprehensive Care and Delivery of Care.61 Comprehensive Care and Delivery of Care: The Developed World.62 The Comprehensive Care and Delivery of Care: The Developing World.63 Comprehensive Care and Delivery of Care: The Global Perspective.Index.